Areva Med, the nuclear medicine subsidiary of Paris-based Areva, has acquired Macrocyclics of Dallas.
Areva Med has developed methods for producing the radioisotope lead-212 (Pb-212), which is used in nuclear medicine research projects to develop new cancer treatments.
Macrocyclics produces chemical agents that attach antibodies or proteins with radioactive isotopes for nuclear medicine treatments targeting aggressive types of cancer, according to Areva.
In January, the U.S. Food and Drug Administration (FDA) gave Areva Med clearance to begin clinical trials for a new therapy using Pb-212 against particularly aggresive types of cancer.
